L-161,638: A potent AT2selective quinazolinone angiotensin II binding inhibitor

The relative AT1 and AT2 binding affinities of 6-amino-2-alkyl-3-[(2′-tetrazole-5-y)biphenyl-4-yl)methyl]quinazolin-4-(3H)-ones can be manipulated by changing the subsitution at positions C-2 and N-6 of the quinazoline nucleus. L-161,6138 was identified as a potent orally bioavailable and AT2selective angiotensin II binding inhibitor.